ENDO PHARM Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ENDO PHARM, and when can generic versions of ENDO PHARM drugs launch?
ENDO PHARM has ten approved drugs.
There are five US patents protecting ENDO PHARM drugs.
There are one hundred and sixty-nine patent family members on ENDO PHARM drugs in thirty-two countries.
Summary for ENDO PHARM
| International Patents: | 169 |
| US Patents: | 5 |
| Tradenames: | 7 |
| Ingredients: | 5 |
| NDAs: | 10 |
| PTAB Cases with ENDO PHARM as petitioner: | See PTAB cases with ENDO PHARM as petitioner |
| PTAB Cases with ENDO PHARM as patent owner: | See PTAB cases with ENDO PHARM as patent owner |
Drugs and US Patents for ENDO PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Endo Pharms | SYMMETREL | amantadine hydrochloride | SYRUP;ORAL | 016023-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-003 | Dec 9, 2011 | DISCN | Yes | No | 8,871,779 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-006 | Dec 9, 2011 | DISCN | Yes | No | 8,114,383 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Endo Pharms | OPANA | oxymorphone hydrochloride | TABLET;ORAL | 021611-002 | Jun 22, 2006 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-002 | Dec 9, 2011 | DISCN | Yes | No | 8,808,737 | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ENDO PHARM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-004 | Dec 9, 2011 | 8,075,872 | ⤷ Subscribe |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-006 | Dec 9, 2011 | 8,309,122 | ⤷ Subscribe |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-004 | Dec 9, 2011 | 8,329,216 | ⤷ Subscribe |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-006 | Dec 9, 2011 | 8,075,872 | ⤷ Subscribe |
| Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-005 | Dec 9, 2011 | 8,075,872 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ENDO PHARM drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-05-29 |
| ➤ Subscribe | Extended-release Tablets | 5 mg, 10 mg, 20 mg and 40 mg | ➤ Subscribe | 2007-11-23 |
| ➤ Subscribe | Extended-release Tablets | 30 mg | ➤ Subscribe | 2008-06-12 |
International Patents for ENDO PHARM Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| European Patent Office | 2102213 | ⤷ Subscribe |
| Ecuador | SP066346 | ⤷ Subscribe |
| Argentina | 049083 | ⤷ Subscribe |
| Canada | 2534932 | ⤷ Subscribe |
| Canada | 2595954 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
